Navigation Links
CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
Date:4/1/2009

antagonists targeting the CB1 receptor, such as agents being developed to treat obesity, have been associated with such central side effects as negative mood and depression. Furthermore, cannabinoid agonists targeting CB1 receptors, including candidates being developed for pain relief, have demonstrated the potential for abuse. By acting selectively at the periphery rather than in the CNS, the CeNeRx cannabinoid compounds have the potential for good therapeutic efficacy without these adverse effects.

Mr. Brand added, "Issuance of this new patent also reinforces the ongoing value of our collaboration with our discovery partner PharmaNess, who played a central role in identifying the structure-activity relationship of this series and in running key preclinical models that validated the role of these compounds in a range of conditions including glaucoma, pain, obesity and spasticity. We look forward to continuing to collaborate with them on this and potentially other programs."

CeNeRx obtained exclusive worldwide rights to develop, manufacture and commercialize its cannabinoid compounds from PharmaNess Neuroscience in Italy. The collaboration between CeNeRx and PharmaNess also includes drug discovery efforts aimed at further expanding the cannabinoid portfolio. CeNeRx has market exclusivity for the cannabinoid series of compounds beyond 2025.

The new patent, US 7,485,730 B2 issued on February 3, 2009.

About CeNeRx BioPharma

CeNeRx is a privately held clinical stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for the treatment of major depressive disorder. RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profile. The company's C
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CeNeRx BioPharma Completes $15 Million Series B Financing
2. DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments
3. Maryland Business, Academic and Biopharma Groups Underscore Commitment to Medical Innovation, Finding Cures and Supporting the Economy
4. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
5. Helix BioPharma Announces Q2 2009 Financial Results
6. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
7. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
8. DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors
9. Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
10. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
11. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Dr Jaspreet Singh , Senior ... deliver a speech at the 2015 Asian Starch Conference, to ... Expo Center.  , ... the topic: ,Potato Starch: A Potential Source for the ... Co-editor of a 528 page text book entitled ...
(Date:5/5/2015)... N.J. , May 5, 2015 Roka Bioscience, ... on providing advanced testing solutions for the detection of foodborne ... present at the Bank of America Merrill Lynch 2015 Health ... will be held at Encore at the Wynn, ... webcast of the presentation will be available through the investor ...
(Date:5/5/2015)... , May 5, 2015 Psyche Systems Corporation ... which offers a first-of-its-kind platform that helps labs comply ... lab results, transforms the way patients engage with these ... Luminate Health provides a HIPAA-compliant digital platform that ... manage, and understand their lab results, and uniquely connects ...
(Date:5/5/2015)... May 5, 2015 ImmunoCellular Therapeutics, Ltd. ... Gengos , President and Chief Executive Officer, will ... DATE:  Thursday, May 7, 2015     TIME:  11:30 ... > click the red "register/ watch presentations" ... interactive online event where investors are invited to ...
Breaking Biology Technology:Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2
... Nov. 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... Credit Suisse 18th Annual Healthcare Conference on Wednesday, November ... Time). Interested parties may access a live webcast ... http://www.onyx-pharm.com/view.cfm/32/Event-Calendar , It is recommended that listeners ...
... , NORRISTOWN, Pa., Nov. 4 ... premier pharmaceutical solutions company, today announced that it has ... , a contract research organization that specializes in ... business development capabilities. The exclusive partnership leverages the expertise ...
... BOZEN, Italy, November 4 Health Robotics ... i.v.SOFT Workflow Engine at,the American Society of Health-System Pharmacists, ... of the i.v.SOFT Workflow Engine,Health Robotics becomes the first ... automation solution to fill the void of automated process ...
Cached Biology Technology:Emerson Resources Forges Strategic Partnership with Bio Research 2Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas 2Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas 3
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... American Dietetic Association has published an updated position paper ... people with developmental disabilities and special health care needs. ... of technology and the importance of services provided by ... paper, published in the February issue of the ...
... made from tobacco plants has been shown to arrest ... by Arizona State University scientist Qiang Chen and his ... University,s Biodesign Institute and professor in the PolyTechnic Campus, ... demonstrate a plant-derived treatment to successfully combat West Nile ...
... Calif. Biologist Cheryl Hayashi , who studies spider ... to present her work at the prestigious TED Conference ... this year,s TED Conference are Feb. 9-13. Hayashi,s talk ... She is one of about 50 speakers at ...
Cached Biology News:Nutrition services, prevention important in nutrition care for special health needs 2Tobacco plant-made therapeutic thwarts West Nile virus 2Tobacco plant-made therapeutic thwarts West Nile virus 3Tobacco plant-made therapeutic thwarts West Nile virus 4UC Riverside biologist is invited speaker at TED Conference 2
... is a fixative useful for routine procedures. ... is stable and will decalcify small bone ... can be stained successfully with most stains, ... stabilizes red blood cell membranes and cosinophil ...
... is a fixative useful for routine procedures. ... is stable and will decalcify small bone ... can be stained successfully with most stains, ... stabilizes red blood cell membranes and cosinophil ...
Chicken polyclonal antibody to Glutathione-S-Transfrease (GST)...
... microarray informatics platform for microarray data storage, data ... use it forever without paying ongoing license fees. ... has all the analysis tools you need to ... control statistics and normalization, all the way through ...
Biology Products: